Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Validation of Daraex to Resolve Daratumumab-Induced Interferences in Pre-Transfusion Screen Tests

Maria Tenorio, PhD, Gemma Moreno Jiménez, MD, Valentín García Gutiérrez, PhD, Ana Jiménez, Maria Jesús Blanchard, MD, Ana Vallés, Sandra López, Pilar Herrera, MD, Javier Lopez Jimenez, MD PhD, Anabelle Chinea, MD

Blood (2019) 134 (Supplement_1): 4983.

https://doi.org/10.1182/blood-2019-131345

Published: 2019

Journal Articles

Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft

Blood (2017) 129 (19): 2680–2692.

https://doi.org/10.1182/blood-2016-09-739722

Published: 2017

Includes: Supplemental data

Journal Articles

High Dose Sargramostim (GM-CSF) Combined with IV Plerixafor for the Mobilization of Peripheral Blood Stem Cells (PBSC) From Normal HLA-Matched Allogeneic Sibling Donors Results in Hypercoagulability

Mark A. Schroeder, MD, Sandra Lopez, MD, Michael P. Rettig, PhD, Kathryn Trinkaus, PhD, Peter Westervelt, John F. DiPersio, MD, PhD

Blood (2012) 120 (21): 4095.

https://doi.org/10.1182/blood.V120.21.4095.4095

Published: 2012

Journal Articles

Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity

Lishomwa C. Ndhlovu, Sandra Lopez-Vergès, Jason D. Barbour, R. Brad Jones, Aashish R. Jha, Brian R. Long, Eric C. Schoeffler, Tsuyoshi Fujita, Douglas F. Nixon, Lewis L. Lanier

Blood (2012) 119 (16): 3734–3743.

https://doi.org/10.1182/blood-2011-11-392951

Published: 2012

Includes: Supplemental data

Journal Articles

Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C + natural killer cells with potent function

Bree Foley, Sarah Cooley, Michael R. Verneris, Michelle Pitt, Julie Curtsinger, Xianghua Luo, Sandra Lopez-Vergès, Lewis L. Lanier, Daniel Weisdorf, Jeffrey S. Miller

Blood (2012) 119 (11): 2665–2674.

https://doi.org/10.1182/blood-2011-10-386995

Published: 2012

Includes: Supplemental data

Journal Articles

Outcomes of Patients Receiving Allogeneic Peripheral Blood Stem Cell Products Mobilized with Intravenous Plerixafor

Mark A. Schroeder, MD, Michael P. Rettig, PhD, Sandra Lopez, MD, Fazia Mir, MD, Kathryn Trinkaus, PhD, Geoffrey L. Uy, MD, John F. DiPersio, MD, PhD

Blood (2011) 118 (21): 314.

https://doi.org/10.1182/blood.V118.21.314.314

Published: 2011

Journal Articles

Natural Killer (NK) Cells Respond to CMV Reactivation After Allogeneic Transplantation with An Increase in NKG2C + CD57 + Self-KIR + NK Cells with Potent IFNγ Production

Bree Foley, PhD, Michael R Verneris, MD, Julie Curtsinger, PhD, Sandra Lopez-Verges, Lewis L. Lanier, PhD, Daniel J. Weisdorf, MD, Sarah Cooley, MD, Jeffrey S. Miller, MD

Blood (2011) 118 (21): 356.

https://doi.org/10.1182/blood.V118.21.356.356

Published: 2011

Journal Articles

Rapid and Prolonged Mobilization of Human CD34+ Hematopoietic Stem Cells Following Intravenous (IV) Administration of Plerixafor

Michael P. Rettig, PhD, Sandra Lopez, MD, Kyle McFarland, John F. DiPersio, MD, PhD

Blood (2010) 116 (21): 2261.

https://doi.org/10.1182/blood.V116.21.2261.2261

Published: 2010

Journal Articles

CD57 defines a functionally distinct population of mature NK cells in the human CD56 dim CD16 + NK-cell subset

Sandra Lopez-Vergès, Jeffrey M. Milush, Suchitra Pandey, Vanessa A. York, Janice Arakawa-Hoyt, Hanspeter Pircher, Philip J. Norris, Douglas F. Nixon, Lewis L. Lanier

Blood (2010) 116 (19): 3865–3874.

https://doi.org/10.1182/blood-2010-04-282301

Published: 2010

Includes: Supplemental data

Journal Articles

Preferential Mobilization of CD34+ Plasmacytoid Dendritic Cell Precursors by Plerixafor.

Michael P. Rettig, PhD, Kyle McFarland, Julie Ritchey, Matthew Holt, Elena Deych, PhD, Sandra Lopez, Jeremy Gabriel, Stephanie L Bauer, FNP, Amanda F Cashen, MD, John F. DiPersio, MD, PhD

Blood (2009) 114 (22): 32.

https://doi.org/10.1182/blood.V114.22.32.32

Published: 2009

Journal Articles

Characterization of Human CD34+ Hematopoietic Stem Cells Following Administration of G-CSF or Plerixafor

Michael P. Rettig, PhD, William D. Shannon, PhD, Julie Ritchey, Matthew Holt, Kyle McFarland, Sandra Lopez, Jeremy Gabriel, John F. DiPersio, MD, PhD

Blood (2008) 112 (11): 3476.

https://doi.org/10.1182/blood.V112.11.3476.3476

Published: 2008

Journal Articles

Kinetics of Stem Cell and Lymphoid Subset Mobilization in Response to Intravenous (IV) AMD3100 in Mouse and Man.

Michael P. Rettig, PhD, Pablo Ramirez, M.D., William D. Shannon, Ph.D., Geoffrey L. Uy, M.D., Sandra Lopez, Julie K. Ritchey, John F. DiPersio, M.D./Ph.D.

Blood (2007) 110 (11): 1203.

https://doi.org/10.1182/blood.V110.11.1203.1203

Published: 2007

Journal Articles

A Mobilizing Regimen of AMD3100 and G-CSF Increases Stem Cell Collection in Patients with Hodgkin’s Disease, and PK Is Similar to That of Non-Cancer Patients.

Amanda F. Cashen, MD, Gary Calandra, M.D., Ph.D., Ron MacFarland, Ph.D., Sandra Lopez, M.D., John F. DiPersio, M.D., Ph.D.

Blood (2006) 108 (11): 3053.

https://doi.org/10.1182/blood.V108.11.3053.3053

Published: 2006

Journal Articles

Presence of Proteinase 3 in Secretory Vesicles: Evidence of a Novel, Highly Mobilizable Intracellular Pool Distinct From Azurophil Granules: Presented in part at the 17th European Workshop on the Cell Biology of Phagocytes, Catania, Italy, May 1998.

Véronique Witko-Sarsat, Elisabeth M. Cramer, Corinne Hieblot, Josette Guichard, Patrick Nusbaum, Sandra Lopez, Philippe Lesavre, Lise Halbwachs-Mecarelli

Blood (1999) 94 (7): 2487–2496.

https://doi.org/10.1182/blood.V94.7.2487.419k07_2487_2496

Published: 1999

NARROW

Validation of Daraex to Resolve Daratumumab-Induced Interferences in Pre-Transfusion Screen Tests

Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft

High Dose Sargramostim (GM-CSF) Combined with IV Plerixafor for the Mobilization of Peripheral Blood Stem Cells (PBSC) From Normal HLA-Matched Allogeneic Sibling Donors Results in Hypercoagulability

Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity

Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C + natural killer cells with potent function

Outcomes of Patients Receiving Allogeneic Peripheral Blood Stem Cell Products Mobilized with Intravenous Plerixafor

Natural Killer (NK) Cells Respond to CMV Reactivation After Allogeneic Transplantation with An Increase in NKG2C + CD57 + Self-KIR + NK Cells with Potent IFNγ Production

Rapid and Prolonged Mobilization of Human CD34+ Hematopoietic Stem Cells Following Intravenous (IV) Administration of Plerixafor

CD57 defines a functionally distinct population of mature NK cells in the human CD56 dim CD16 + NK-cell subset

Preferential Mobilization of CD34+ Plasmacytoid Dendritic Cell Precursors by Plerixafor.

Characterization of Human CD34+ Hematopoietic Stem Cells Following Administration of G-CSF or Plerixafor

Kinetics of Stem Cell and Lymphoid Subset Mobilization in Response to Intravenous (IV) AMD3100 in Mouse and Man.

A Mobilizing Regimen of AMD3100 and G-CSF Increases Stem Cell Collection in Patients with Hodgkin’s Disease, and PK Is Similar to That of Non-Cancer Patients.

Presence of Proteinase 3 in Secretory Vesicles: Evidence of a Novel, Highly Mobilizable Intracellular Pool Distinct From Azurophil Granules: Presented in part at the 17th European Workshop on the Cell Biology of Phagocytes, Catania, Italy, May 1998.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only